Candel Therapeutics CADL
NASDAQ CADL
$10.18 +0.02 (+0.20%)
At close: Oct 2, 2026 · 4:00 PM EDT

Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2026)

Updated

Candel Therapeutics (CADL) posted Non-Current Deffered Revenue of $45,000 for Q2 2026.

Analysis

Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends

At the end of FY2025, Candel Therapeutics' Non-Current Deffered Revenue came in at $89,000.

  • Annual Non-Current Deffered Revenue shows a five-year compound annual growth rate of -6.6% (FY2020 to FY2025).
  • In prior years, Candel Therapeutics' Non-Current Deffered Revenue was $144,000 in FY2022.
  • The Q2 2026 figure stands as the lowest quarterly Non-Current Deffered Revenue since Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn -
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn -
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn -
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn -
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -
10 Candel Therapeutics 773.36 Mn 773.36 Mn - 45,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 45,000.00
Dec 31, 2025 89,000.00
Sep 30, 2023 108,000.00
Jun 30, 2023 120,000.00
Mar 31, 2023 132,000.00
Dec 31, 2022 144,000.00
Sep 30, 2021 31,000.00
Jun 30, 2021 63,000.00
Dec 31, 2020 125,000.00
API Access

Candel Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=CADL&period=max&api_key=YOUR_API_KEY